Get Updates

No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > PARP Inhibitor Therapy

| More

BRCA & HBOC
Toggle Menu

PARP Inhibitor Therapy

Learn how genetic test results may affect medical decisions about cancer treatment.”

Niraparib for Breast Cancer

Phase 1 clinical trial results presented at the 2013 ASCO meeting showed that the PARP inhibitor niraparib is active against breast cancer and high-grade ovarian cancer. 

A phase III clinical trial called BRAVO is currently recruiting patients with metastatic or advanced breast cancer who have a BRCA1 or BRCA2 mutation. Participation in the BRAVO trial is restricted to patients who have responded well to prior surgery or radiation, and who may have had one or two prior chemotherapies.  It will compare outcomes for patients who recieve niraparib compared with patients who receive standard chemotherapy.

Updated 12/27/16

FORCE:Facing Our Risk of Cancer Empowered